Dillon & Associates Inc. Boosts Holdings in Novo Nordisk A/S $NVO

Dillon & Associates Inc. grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 3.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 303,883 shares of the company’s stock after buying an additional 8,769 shares during the period. Novo Nordisk A/S makes up 2.8% of Dillon & Associates Inc.’s holdings, making the stock its 9th biggest position. Dillon & Associates Inc.’s holdings in Novo Nordisk A/S were worth $20,968,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in NVO. Stone House Investment Management LLC acquired a new stake in Novo Nordisk A/S in the first quarter valued at about $30,000. NewSquare Capital LLC boosted its stake in Novo Nordisk A/S by 174.1% in the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after buying an additional 282 shares in the last quarter. Disciplina Capital Management LLC boosted its stake in Novo Nordisk A/S by 162.3% in the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock valued at $33,000 after buying an additional 297 shares in the last quarter. Dagco Inc. acquired a new stake in shares of Novo Nordisk A/S during the first quarter valued at about $35,000. Finally, Mid American Wealth Advisory Group Inc. acquired a new stake in shares of Novo Nordisk A/S during the second quarter valued at about $37,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $49.11 on Tuesday. The company has a market cap of $219.26 billion, a price-to-earnings ratio of 13.49, a price-to-earnings-growth ratio of 2.33 and a beta of 0.68. Novo Nordisk A/S has a 52 week low of $45.05 and a 52 week high of $112.52. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The firm has a 50 day moving average of $56.03 and a 200-day moving average of $61.85.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.93 by $0.04. The company had revenue of $11.69 billion during the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. On average, equities analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were issued a dividend of $0.4119 per share. The ex-dividend date was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S’s payout ratio is currently 22.53%.

Analyst Ratings Changes

A number of brokerages have recently commented on NVO. Weiss Ratings reissued a “hold (c)” rating on shares of Novo Nordisk A/S in a research note on Tuesday, October 14th. Barclays reissued an “equal weight” rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. TD Cowen cut their price target on Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, August 19th. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Finally, Hsbc Global Res raised Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $76.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.